Ocrelizumab 300mg/10ml solution for infusion vials
NHS hospitals in England used £164,407,170 of indicative cost of Ocrelizumab 300mg/10ml solution for infusion vials in the 12 months to July 2026, about 0.6% of all hospital medicines spend. That is down 16.4% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Ocrelizumab 300mg/10ml solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Ocrelizumab 300mg/10ml solution for infusion vials most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Imperial College Healthcare Nhs Trust | £23,284,190 |
| Univ Hpl B/Ham Nhs Foundation Trust | £10,049,420 |
| Barts Health Nhs Trust | £9,158,480 |
| Sheffield Teaching Hospitals Nhs Trust | £9,009,990 |
| University Hpls North Midlands Nhs Trust | £7,654,420 |
| King's College Hpl Nhs Foundation Trust | £6,068,930 |
| University College London Foundation Tr | £5,762,370 |
| Leeds Teaching Hpls Nhs Trust | £5,101,350 |
| St George's Univ Hosps Foundation Nhst | £4,282,260 |
| Salford Royal Nhs Foundation Trust | £4,239,150 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.